Legend Biotech Corporation (LEGN)

NMS – Real Time Price. Currency in USD

28.26

+2.68 (10.48%)

At close: May 12, 2026, 4:00 PM EDT

28.14

-0.12 (-0.42%)

Pre-market: May 13, 2026, 8:01 AM EDT

12.05.2026

Legend Biotech Corporation (LEGN) Q1 2026 Earnings Call Transcript

12.05.2026

Legend Biotech Q1 Earnings Call Highlights

Legend Biotech NASDAQ: LEGN reported sharply higher first-quarter 2026 sales for CARVYKTI, its CAR T therapy for multiple myeloma, as management said demand continued to move into earlier lines of treatment and international markets expanded.

12.05.2026

Legend Biotech Reports First Quarter 2026 Results and Recent Highlights

CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 62% versus first quarter of 2025 to approximately $597 million CARVYKTI ® now available across 18 global markets, following recent launches in Italy, Poland, the Czech Republic, and Australia Advanced early-stage cell therapy portfolio, with multiple data presentations expected at medical conferences in 2026 Cash and cash equivalents, and time deposits of $834.6 million, as of March 31, 2026 . SOMERSET, N.J.

04.05.2026

Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth

SOMERSET, N.J., May 04, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the engagement with a group of distinguished scientific advisors who will provide strategic input as Legend advances its pipeline and future research priorities.

28.04.2026

Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results

SOMERSET, N.J., April 28, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, May 12, 2026, to review first quarter 2026 financial results.

24.04.2026

Legend Biotech: Undervalued Leader In The CAR-T Race

In my opinion, Legend Biotech Corporation is an attractive acquisition target for Johnson & Johnson. Carvykti, which they are jointly developing, is quickly catching up in sales with Darzalex, J&J's blockbuster for the treatment of multiple myeloma. So, sales of Carvykti reached $597 million in Q1, up 61.8% year-on-year, beating my 'best case' scenario by $15 million.

21.04.2026

Legend Biotech (LEGN) Moves 18.4% Higher: Will This Strength Last?

Legend Biotech (LEGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Videos

No Data

There is no data to display

Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

SOMERSET, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported financial results for the fourth quarter and year ended December 31, 2025, and key corporate highlights.

06.12.2025

Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025

SOMERSET, N.J., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced new long-term clinical and translational data for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) from the CARTITUDE-1 and CARTITUDE-4 studies in relapsed / refractory multiple myeloma (RRMM) patients. In triple-class-exposed patients who had received three prior lines of therapy, a median progression-free survival (mPFS) of 50.4 months was observed following a single infusion of CARVYKTI®. This represents one of the longest PFS outcomes reported for a BCMA-targeted CAR-T cell therapy in this heavily pretreated population.

Legend Biotech Corporation (LEGN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Legend Biotech Corporation (LEGN)

Legend Biotech Corporation (LEGN) Q1 2026 Earnings Call Transcript

Legend Biotech Q1 Earnings Call Highlights

Legend Biotech Reports First Quarter 2026 Results and Recent Highlights

Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth

Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results

Legend Biotech: Undervalued Leader In The CAR-T Race

Legend Biotech (LEGN) Moves 18.4% Higher: Will This Strength Last?

Videos

No Data

Press releases

Legend Biotech Reports First Quarter 2026 Results and Recent Highlights

Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth

Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025

Legend Biotech Corporation (LEGN) Q1 2026 Earnings Call Transcript

Legend Biotech Q1 Earnings Call Highlights

Legend Biotech Reports First Quarter 2026 Results and Recent Highlights

Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth

Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results

Legend Biotech: Undervalued Leader In The CAR-T Race

Legend Biotech (LEGN) Moves 18.4% Higher: Will This Strength Last?

Videos

No Data

Press releases

Legend Biotech Reports First Quarter 2026 Results and Recent Highlights

Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth

Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025

Search stocks

Legend Biotech Corporation (LEGN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Legend Biotech Corporation (LEGN)

Legend Biotech Corporation (LEGN) Q1 2026 Earnings Call Transcript

Legend Biotech Q1 Earnings Call Highlights

Legend Biotech Reports First Quarter 2026 Results and Recent Highlights

Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth

Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results

Legend Biotech: Undervalued Leader In The CAR-T Race

Legend Biotech (LEGN) Moves 18.4% Higher: Will This Strength Last?

Videos

No Data

Press releases

Legend Biotech Reports First Quarter 2026 Results and Recent Highlights

Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth

Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025

Legend Biotech Corporation (LEGN) Q1 2026 Earnings Call Transcript

Legend Biotech Q1 Earnings Call Highlights

Legend Biotech Reports First Quarter 2026 Results and Recent Highlights

Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth

Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results

Legend Biotech: Undervalued Leader In The CAR-T Race

Legend Biotech (LEGN) Moves 18.4% Higher: Will This Strength Last?

Videos

No Data

Press releases

Legend Biotech Reports First Quarter 2026 Results and Recent Highlights

Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth

Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025